Cerulean Pharma Selected as One of America’s Most Promising Companies by Forbes

December 1, 2011

CAMBRIDGE, Mass. – December 1, 2011 – Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced that Forbes has named it one of America’s Most Promising Companies in 2011.

“We are thrilled to be recognized by Forbes editors as a top 100 privately held company in the U.S., and we are truly honored that Cerulean is the only biotechnology company represented on the list,” said Oliver Fetzer, Ph.D., chief executive officer of Cerulean. “This has been an exciting year for Cerulean as we are making tremendous progress in our clinical development and research programs, advancing nanopharmaceuticals as a new class of tumor-targeted cancer therapy.”

In July 2011, Cerulean initiated a randomized Phase 2 study of its lead clinical nanopharmaceutical candidate, CRLX101, for the treatment of advanced non-small cell lung cancer. Additionally, the Company has generated compelling non-clinical data in its nucleic acid nanopharmaceutical program which demonstrates targeting of intact siRNA to tumor tissue, entry of the siRNA into cancer cells, and achievement of durable gene silencing in these cancer cells. These data will be presented in RNAi scientific conferences in early 2012 and will highlight the potential of Cerulean’s platform to address the challenges that have stalled the development of RNAi-based therapeutics.

About Forbes’ List of America’s Most Promising Companies Forbes’ list of America’s Most Promising Companies features 100 privately held up-and- comers with compelling business models, strong management teams, notable customers, strategic partners and precious investment capital.
“Sizing up younger, privately held companies is hard, as their fortunes can change very quickly and there’s a dearth of public data,” says Forbes Executive Editor Brett Nelson. “We took a more comprehensive approach to evaluate their health and potential.”

To sharpen its search, Forbes teamed up with CB Insights, a Manhattan-based data firm that tracks investment in high-growth private companies. With $650,000 in grants from the National Science Foundation, CB has developed complex software called Mosaic that mines myriad online sources (from press releases and social networks to job boards and court filings) to come up with one, algorithmically derived score that measures a private company’s health. Forbes married Mosaic’s data-crunching with old-fashioned reporting to assemble a list of rising stars with bright growth prospects. To view the complete the list, please visit www.forbes.com/ampc.


About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at http://www.ceruleanrx.com.


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.